Inventiva S.A (IVEVF PINK) stock market data APIs
$5.284
0(0%)
as of May 19, 2026
Try our APIs with
free plan!
Inventiva S.A Financial Data Overview
Price chart is built with
Anychart
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Prev. Close
5.284
Open
5.284
High
5.284
Low
5.284
52 wk Range
2.28-5.75
Market Cap
1 114 M
Shares Outstanding
209 M
Revenue
6 761 K
EPS
-0.4384
Beta
0.883
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inventiva S.A data using free add-ons & libraries
Get Inventiva S.A Fundamental Data
Inventiva S.A Fundamental data includes:
- Net Revenue: 6 761 K
- EBITDA: -132 497 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-05-12
- EPS/Forecast: -0.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inventiva S.A News
New
This is Why Wall Street is Bullish on Inventiva S.A. (IVA)
Inventiva S.A. (NASDAQ:IVA) is one of the best multibagger penny stocks to buy right now. Inventiva (NASDAQ:IVA) commands a consensus Buy rating on Wall Street. The average price target for the stock ...
Inventiva S.A. reports nine-months results
* Inventiva S.A. press release [https://seekingalpha.com/pr/20317481-inventiva-reports-2025-third-quarter-financial-information] (OTCPK:IVEVF [https://seekingalpha.com/symbol/IVEVF]): Revenues of �...
Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target
Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ:IVA)...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
INVENTIVA Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company fo...
Get Inventiva S.A fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
